611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Health Tip: Recognizing a Staph InfectionIs Dairy Fat Different?CDC Recommends Catch-Up HPV Vaccination for Young AdultsHow to Relieve Dry, Irritated EyesPretomanid Approved for Treatment of Drug-Resistant TBAHA News: Tiring Easily May Warn of Future Heart TroubleAmerica's Obesity Epidemic May Mean Some Cancers Are Striking SoonerHeavy Smog as Bad as Pack-a-Day Smoking for LungsConcussed NFL Players Sidelined for Much Longer NowadaysHormone Therapy for Prostate Cancer Might Harm the Heart: StudyObesity and 'Spare Tire' Raise Hispanics' Odds for Early DeathAHA News: Protein Made During Long Workouts May Warn of Heart ProblemsHow to Help Your Heart Weather Extreme HeatHealth Threats Don't End for Some Sepsis SurvivorsHeat Waves Brought by Climate Change Could Prove Deadly for Kidney PatientsHealth Tip: Avoiding AnemiaAre You Still Putting Off Colon Cancer Screening?Tips for Preventing DiverticulitisFDA Reports More Seizures Among VapersKids Getting Too Many Opioids After TonsillectomyCan Major Surgeries Cause a Long-Term 'Brain Drain'?How Much Coffee Is Too Much for Migraine Sufferers?Steady Stream of Lesser Head Hits in Football Can Still Damage BrainDon't Sweat It: Hyperhydrosis Can Be TreatedFast-Food Joints on Your Way to Work? Your Waistline May WidenAdults Need Vaccines, TooHealth Tip: Managing Arthritis of the Hands'Selfies' Might Someday Track Your Blood PressureIn Heat Waves, Fans May Do More Harm Than GoodSmoking Creates Long-Lasting Risk for Clogged Leg ArteriesFootball Head Trauma Linked Again to Long-Term Brain DamageDrug Approved to Treat Tenosynovial Giant Cell TumorRugby-Style Tackling Might Make Football SaferFor Kids With Asthma, Allergies, New School Year Can Bring Flare-UpsFrailty Not a Normal Part of AgingAHA News: Hurricane Checklist: Batteries, Bottled Water – And A Plan for Heart CareDangerous Sesame Allergy Affects Many AmericansScorching Pavement Sends Some to the ER With BurnsHealth Tip: Living With Hypoglycemia3-D Printers Might Someday Make Replacement HeartsCDC Renews Pledge to Fight Ebola Outbreak in AfricaAnemia Linked to Higher Odds for Dementia in SeniorsDrug Duo May Be an Advance Against a Common LeukemiaAHA News: Chemical Widely Used in Medical Plastic Alters Heart Function in Lab TestsHigh Blood Pressure Much More Deadly for the PoorHealth Tip: Understanding PrediabetesMild Head Injury Can Impair Your Sense of SmellMiddle Age Now a High-Risk Time for Bad FallsSmoking May Interfere With 'Embolization' Lung TreatmentHeartburn Drugs Might Bring Allergy Woes
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Drug Approved to Treat Tenosynovial Giant Cell Tumor


HealthDay News
Updated: Aug 5th 2019

new article illustration

MONDAY, Aug. 5, 2019 (HealthDay News) -- Turalio (pexidartinib) capsules have been approved to treat adults with symptomatic tenosynovial giant cell tumor (TGCT), the U.S. Food and Drug Administration announced.

The drug was approved for patients with TGCT with severe morbidity or functional limitations that has not improved with surgery. Turalio is only available through the Risk Evaluation and Mitigation Strategy Program.

Approval was based on data from a multicenter international clinical trial of 120 patients. After 25 weeks, patients who received Turalio had a statistically significant improvement in overall response rate (ORR) to an ORR of 38 percent versus no response in patients who received placebo. Fifteen percent of patients had a complete response and 23 percent had a partial response. Among patients followed for a minimum of six months following initial response, 22 of 23 patients maintained their response for six months or longer; all 13 patients who initially responded and were followed for a minimum of 12 months maintained their response for 12 months or longer.

Commonly reported side effects include lactate dehydrogenase, increased aspartate aminotransferase, loss of hair color, increased alanine aminotransferase, and increased cholesterol. Side effects also include neutropenia, increased alkaline phosphatase, decreased lymphocytes, eye edema, decreased hemoglobin, rash, dysgeusia, and decreased phosphate. A Boxed Warning on the prescription information for Turalio warns about the risk for serious and potentially fatal liver injury and advises health care professionals to monitor patients' liver tests before and during treatment and to alter or discontinue use of the drug if liver tests are abnormal.

Approval was granted to Daiichi Sankyo.

More Information